QNRX vs MSFT: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

MSFT has stronger fundamentals based on our AI analysis.

QNRX
Quoin Pharmaceuticals, Ltd.
STRONG SELL
85%
Confidence
VS
MSFT
MICROSOFT CORP
BUY
91%
Confidence

QNRX vs MSFT Fundamental Comparison

Metric QNRX MSFT
Revenue N/A $158.9B
Net Income $-15.8M $66.2B
Net Margin N/A 41.7%
ROE -120.5% 16.9%
ROA -77.5% 10.0%
Current Ratio 3.61x 1.39x
Debt/Equity 0.00x 0.10x
EPS N/A $8.87

Green = Better metric | Red = Weaker metric

View Full QNRX Analysis →
View Full MSFT Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

QNRX vs AAPL MSFT vs GOOGL QNRX vs AMZN MSFT vs NVDA

QNRX vs MSFT: Frequently Asked Questions

Is QNRX or MSFT a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. QNRX is rated STRONG SELL (85% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.

How does QNRX compare to MSFT fundamentally?

Quoin Pharmaceuticals, Ltd. has ROE of -120.5% vs MICROSOFT CORP's 16.9%. Net margins are N/A vs 41.7% respectively.

Which stock pays higher dividends, QNRX or MSFT?

QNRX has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in QNRX or MSFT for long term?

For long-term investing, consider that QNRX has STRONG SELL rating with 85% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about QNRX vs MSFT?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For QNRX vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.